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Abstract. Neuromyelitis optica (NMO) is a refractory auto-
immune inflammatory disease of the central nervous system 
without an effective cure. Autologous bone marrow‑derived 
mesenchymal stem cells (BM‑MSCs) are considered to be 
promising therapeutic agents for this disease due to their 
potential regenerative, immune regulatory and neurotrophic 
effects. However, little is known about the cytological features 
of BM‑MSCs from patients with NMO, which may influence 
any therapeutic effects. The present study aimed to compare 
the proliferation, differentiation and senescence of BM‑MSCs 
from patients with NMO with that of age‑ and sex‑matched 
healthy subjects. It was revealed that there were no significant 
differences in terms of cell morphology or differentiation 
capacities in the BM‑MSCs from the patients with NMO. 
However, in comparison with healthy controls, BM‑MSCs 
derived from the Patients with NMO exhibited a decreased 
proliferation rate, in addition to a decreased expression of 
several cell cycle‑promoting and proliferation‑associated 
genes. Furthermore, the cell death rate increased in BM‑MSCs 
from patients under normal culture conditions and an assess-
ment of the gene expression profile further confirmed that the 
BM‑MSCs from patients with NMO were more vulnerable to 
senescence. Platelet‑derived growth factor (PDGF), as a major 
mitotic stimulatory factor for MSCs and a potent therapeutic 
cytokine in demyelinating disease, was able to overcome the 
decreased proliferation rate and increased senescence defects 
in BM‑MSCs from the patients with NMO. Taken together, 
the results from the present study have enabled the proposition 
of the possibility of combining the application of autologous 
BM‑MSCs and PDGF for refractory and severe patients with 
NMO in order to elicit improved therapeutic effects, or, at the 
least, to include PDGF as a necessary and standard growth 
factor in the current in vitro formula for the culture of NMO 
patient‑derived BM‑MSCs.
Introduction
Neuromyelitis optica (NMO) is a severely disabling inflamma-
tory disease of the central nervous system that predominantly 
affects the optic nerves and the spinal cord (1). The prevalence 
of NMO worldwide ranges from 0.5‑4.4 cases per 100,000 (2,3) 
and the mortality rate directly associated with NMO attacks 
ranges from 7 to 30%, predominantly attributable to neurogenic 
respiratory failure (4‑6). Most of the treatments for acute attacks 
and NMO relapses are targeted to controlling the symptoms, 
although large‑scale randomized trials have been too scarce 
to allow optimization of the treatment strategies for NMO (7). 
Furthermore, immune modulatory and anti‑inflammatory 
agents have not been demonstrated to influence the course of 
NMO progression and therefore are not suitable for curing 
chronic neurological disability. Therefore, novel treatment 
modalities to alleviate the disability resulting from NMO have 
evoked considerable interest. Much attention has been focused 
on restorative therapy, particularly the use of stem cells.
Mesenchymal stem cells (MSCs) are adult non‑hemato-
poietic pluripotent cells with a high capacity to be induced to 
differentiate into other cell lines, including adipocytes, chon-
drocytes and stromal cells (8). Certain characteristics make 
MSCs attractive as therapeutic candidates, including innate 
pluripotency, the capacity to facilitate the repair of lesions 
through multiple avenues in immune regulation, angiogenesis 
and neurogenesis, and their immune privileged status (9). MSCs 
may be isolated from various sources, including bone marrow, 
adipose tissue (10), umbilical cord (11) and peripheral blood, 
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among which the major and most frequently studied source is 
the bone marrow. Furthermore, a growing body of pre‑clinical 
studies has consistently demonstrated that bone marrow‑derived 
MSCs (BM‑MSCs) are capable of safely ameliorating clinical 
outcomes of certain neurological degenerative diseases, 
including stroke (12) and multiple sclerosis (13,14).
A recent paper published by the authors' laboratory revealed 
that the transplantation of autologous BM‑MSCs exerted posi-
tive effects in the treatment of NMO (15). However, little is 
known about the cytological features of BM‑MSCs from 
patients with NMO. In the present study, a comprehensive 
comparison of the cytological features of BM‑MSCs from 
patients with NMO and healthy subjects was conducted. 
The results obtained will provide a general understanding of 
BM‑MSCs derived from patients with NMO and may assist 
in the optimization of culture and cell proliferation protocols, 
thereby leading to improved MSC transplantation results.
Materials and methods
Patients. Informed consent was obtained from all participants 
in the present study and the study was approved by the Tianjin 
Medical University General Hospital Institutional Review Board 
and Ethics Committee (Tianjin, China). Patients with NMO 
were recruited between January 2016 and December 2017 from 
Tianjin Medical University General Hospital. The five patients 
(all female; patient characteristics are presented in Table SI) were 
enrolled on the basis of the following criteria: i) They conformed 
with the diagnostic criteria proposed by Wingerchuk et al (3) 
in 2007; ii) exclusion criteria included a history of diabetes, 
cardio‑ or cerebrovascular diseases and inflammatory, and auto-
immune diseases other than NMO; iii) none of the patients had 
received corticosteroid or other immunosuppressant therapy 
within the last 4 weeks; and iv) all patients exhibited no other 
autoimmune diseases and all patients with NMO were moni-
tored over a one year period (detailed information are described 
in Table SI). A total of five age‑matched healthy female volun-
teers were enrolled as health controls.
Isolation and identification of BM‑MSCs. Aliquots of 5‑10 ml 
adult donor bone marrow aspirates were provided by the 
Department of Hematology of Tianjin Medical University 
General Hospital. Bone marrow‑derived mononuclear cells 
(BM‑MNCs) were isolated and cultured in Gibco® Dulbecco's 
Modified Eagle Medium/Nutrient Mixture F‑12 (D‑MEM/F‑12 
medium; Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
supplemented with 10% fetal bovine serum (FBS; Hyclone, 
Chicago, IL, USA), 100 U/ml penicillin/streptomycin, 2 mM 
L‑glutamine (Sigma‑Aldrich; Merck KGaA, Darmstadt, 
Germany), 2 ng/ml human basic fibroblast growth factor and 
10 ng/ml human epidermal growth factor (PeproTech, Inc., 
Rocky Hill, NJ, USA). Platelet‑derived growth factor‑BB 
(PDGF‑BB) was also purchased from PeproTech, Inc. 
Following culture at 37˚C in a humid atmosphere with 5% CO2 
for 3 days, the culture medium was completely replaced and 
non‑adherent cells were removed. When the cells had reached 
~80‑85% confluence, the adherent cells were detached by treat-
ment with 0.125% trypsin and 0.1% EDTA (Sigma‑Aldrich; 
Merck KGaA), and put back into the medium at a 1:2 dilution 
under the same culture conditions.
At passage 3, adherent cells were identified by surface 
markers with monoclonal antibodies cluster of differentiation 
(CD)29, CD166, CD44, CD73, CD34 and CD90 (BioLegend, 
Inc., San Diego, CA, USA), CD45 (BD Pharmingen; Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA), CD105 
(Abcam, Cambridge, MA, USA) using a FACS flow cytometer 
(BD Biosciences, Becton, Dickinson and Company; the details 
of all the antibodies are described in Table I).
Morphology of BM‑MSCs. BM‑MSCs were cultured in 
DMEM/F‑12 medium and observed under an inverted light 
microscope. At the same time, BM‑MSCs were stained for 
β‑tubulin for the morphology examination. BM‑MSCs were 
grown on glass chamber slides at 90% confluence and fixed 
with 4% paraformaldehyde at room temperature for 30 min. 
Subsequently, the BM‑MSCs were first permeated with 
cold acetone for 10 min and washed with ice‑cold PBS. The 
BM‑MSCs were then blocked with 5% bovine serum albumin 
(BSA; Sigma‑Aldrich, Merck KGaA) in PBS at room tempera-
ture for 30 min, followed by incubation with rabbit antihuman 
β‑tubulin antibody (Thermo Fisher Scientific, Inc.) overnight 
at 4˚C. After three washes with ice‑cold PBS, the BM‑MSCs 
were incubated with goat tetramethylrhodamine‑conjugated 
goat anti‑rabbit immunoglobulin G secondary antibody 
(Thermo Fisher Scientific, Inc.; details of the antibodies are 
described in the Table II) at room temperature for 30 min and 
their nuclei were stained with 1 µg/µl 4',6‑diamidino‑2‑phe-
nylindole (DAPI) at room temperature for 10 min. The cells 
were then washed twice with ice‑cold PBS and the images 
were visualized using a fluorescence microscope (Nikon 
Corporation, Tokyo, Japan).
Cell proliferation assay. To assess the proliferation state 
of the BM‑MSCs cells following the various treatments an 
MTT (Sigma‑Aldrich; Merck KGaA) proliferation assay was 
performed according to the manufacturer's protocol. In brief, 
BM‑MSCs cells were seeded into 96‑well plates at a density of 
2x104 cells/ml for 1‑4 days. An aliquot of 20 µl MTT labeling 
reagent (5 mg/ml) was added daily to each well and the plates 
were incubated at 37˚C for 4 h. The resulting formazan crystals 
Table I. Phenotype characteristics of bone marrow‑mesen-
chymal stem cells.
Surface Patients with Healthy
marker NMO (%) control (%) P‑value
CD29 98.35 99.01 NS
cd34 - - -
CD44 96.27 95.98 NS
cd45 - - -
CD73 99.15 98.79 NS
CD90 95.30 96.12 NS
CD105 92.28 93.19 NS
CD166 94.25 95.42 NS
CD, cluster of differentiation; NS, not significant; NMO, neuromy-
elitis optica.
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were solubilized by adding 100 µl DMSO per well and the plates 
were incubated at room temperature for 10 min. The absorbance 
of formazan was measured at 575 nm and this was taken as the 
measure for the proliferation state of the cells. Trypan blue cell 
exclusion was also used at room temperature for 5 min to assess 
cell viability and the cell number with a light microscope.
Apoptosis of BM‑MSCs. The apoptotic rate of the BM‑MSCs 
was evaluated using a commercial fluorescein thiocyanate 
(FITC)‑Annexin V apoptosis detection kit (Nanjing KeyGen 
Biotech Co., Ltd., Nanjing, China), as recommended by the 
manufacturer. BM‑MSCs (5x105 cells) were harvested, washed 
and incubated in the Annexin V binding buffer. Subsequently, 
the BM‑MSCs were stained with Annexin V‑FITC and 
propidium iodide (PI), and flow cytometric analysis was then 
performed using a flow cytometer (BD FACSAria™ III) and 
the data were analyzed with FlowJo 7.6 software (FlowJo 
LLC, Ashland, OR, USA). Apoptotic cells were identified in 
the early (FITC‑Annexin V positive, PI negative) and the late 
(FITC‑Annexin V and PI double‑positive) stages.
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR). TRIzol® reagent (Invitrogen; Thermo Fisher 
Scientific, Inc.) was used to isolate total RNA, following the 
manufacturer's protocol and the concentration of total RNA 
was measured using a spectrophotometer following treatment 
with DNase I (Invitrogen; Thermo Fisher Scientific, Inc.). A 
sample (2 µg) of RNA was used for reverse transcription in 
a 20 µl reaction containing EasyScript® reverse transcriptase 
kit (TransGen Biotech Co., Ltd., Beijing, China.). The thermal 
program consisted of 42˚C for 30 min, and then 85˚C for 
5 sec to inactivate enzymes. RT‑qPCR was performed using 
a Bio‑Rad RT‑PCR system instrument (Bio‑Rad Laboratories, 
Inc., Hercules, CA, USA) with an SYBR®‑Green PCR kit 
(Roche Diagnostics, Indianapolis, IN, USA). Genes involved 
in the cell cycle, proliferation and cell apoptosis were selected 
for investigation. Details of all the primers are described 
in Table III. The thermal cycling program consisted of 95˚C 
for 10 min, followed by 40 cycles of 15 sec at 95˚C and 60 sec 
at 60˚C. Relative quantities of target genes were determined 
for unknown samples using the comparative threshold cycle 
(ΔΔCq) method (16) and normalized against GAPDH as the 
control. Each test sample was amplified in three different 
wells with a 20 µl reaction volume, following the manufac-
turer's protocol for each specific experiment and each test was 
repeated at least in triplicate.
Differentiation capacity of BM‑MSCs. BM‑MSCs were 
induced to differentiate into osteoblasts and adipocytes using 
the following procedure. The induction medium for osteogen-
esis was Gibco® Iscove's modified Dulbecco's medium (IMDM; 
Thermo Fisher Scientific, Inc.) supplemented with 10% FBS, 
0.1 µM dexamethasone, 0.2 mM ascorbic acid 2‑phosphate 
and 10 mM glycerol 2‑phosphate (Sigma‑Aldrich; Merck 
KGaA). The induction medium for adipogenesis was IMDM 
supplemented with 10% FBS, 1 µM dexamethasone, 0.5 mM 
3‑isobutyl‑1‑methylxanthine, 10 µg/ml insulin and 60 µM 
indomethacin (Sigma‑Aldrich; Merck KGaA). After 3 days, the 
culture medium was completely replaced and the medium was 
subsequently changed twice weekly thereafter. After the prede-
termined culture time had elapsed, adipocytes were stained 
with Oil Red O at room temperature for 30 min; the osteoblasts 
were identified using alkaline phosphatase (ALP) and Alizarin 
Red S assays were performed at room temperature in the dark 
for 50 min (Sigma‑Aldrich; Merck KGaA).
Western blot analysis. The total proteins of the BM‑MSCs 
were extracted with Pierce™ IP Lysis buffer (Thermo Fisher 
Table II. Antibody information for fluorescence activated cell sorting.
Name Clone ID Manufacturer; cat. no.; RRID Dilution
APC anti‑human CD29 antibody TS2/16 BioLegend, Inc. 303007, RRID:AB_314323;  5 µl per million
  mouse; monoclonal antibody cells in 100 µl
PE anti‑human CD34 antibody 561 BioLegend, Inc.; 343605; RRID:AB_1732033;  staining volume
  mouse; monoclonal antibody
FITC anti‑human CD44 antibody BJ18 BioLegend, Inc.; 338803; RRID:AB_1501204; 
  mouse; monoclonal antibody
PE anti‑human CD166 antibody 3A6 BioLegend, Inc.; 343903; RRID:AB_2289303; 
  mouse; monoclonal antibody
PerCP/Cyanine 5.5 anti‑human CD73 AD2 BioLegend, Inc.; 344013; RRID:AB_2561756; 
  mouse; monoclonal antibody
FITC anti‑human CD90 antibody 5.00E+10 BioLegend, Inc.; 328107; RRID:AB_893438; 
  mouse; monoclonal antibody
PerCP/Cyanine 5.5 anti‑human  MEM‑229 Abcam; ab234265; mouse; monoclonal antibody 
CD105 antibody
APC anti‑human CD45 antibody HI30 BD Biosciences; 560973; RRID:AB_10565969; 
  mouse; monoclonal antibody
CD, cluster of differentiation; FITC, fluorescein isothiocyanate; PE, phycoerythrin; APC, allophycocyanin.
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Scientific, Inc.) and the concentration was determined with 
bicinchoninic acid (BCA) methods with a BCA protein assay 
kit (Beijing Solarbio Science & Technology Co., Lt., Beijing, 
China). The proteins were separated using 10% SDS‑PAGE 
and 15 µg protein were loaded in each lane. Subsequently, the 
proteins were transferred electrophoretically to a polyvinyli-
dene difluoride membranes (Merck KGaA). The membranes 
were blocked with 5% defatted milk at room temperature 
for 1 h and then incubated with the primary antibodies over-
night. The next day, the membranes were incubated with the 
HRP‑conjugated secondary antibodies for 1 h. Protein bands 
were detected using an Amersham ECL Western blotting detec-
tion kit (GE Healthcare Life Sciences, Little Chalfont, UK). 
The protein bands were statistically analyzed with ImageJ 1.4 
software (National Institutes of Health, Bethesda, MD, USA). 
For western blotting analysis, the β‑actin antibody (used as the 
loading control) was purchased from Santa Cruz Biotechnology, 
Inc., (Dallas, TX, USA); the antibodies against cyclin A2 
(CCNA2), cyclin‑dependent kinase inhibitor 2A (CDKN2A), 
amphiregulin (AREG) and Bcl‑xl were from Cell Signaling 
Technology, Inc., (Danvers, MA, USA); and the anti‑Fas anti-
body came from R&D Systems, Inc., (Minneapolis, MN, USA). 
All antibodies are described in further detail in Table II.
Statistical analysis. Each experiment was repeated at least 
three times. All data are presented as the mean ± standard 
deviation. The difference between means was statistically 
analyzed using a t‑test. All statistical analyses were performed 
using GraphPad Prism 6 software (GraphPad Software, Inc., 
La Jolla, CA, USA). P<0.05 was considered to indicate a statis-
tically significant difference.
Results
NMO patient‑derived BM‑MSCs exhibit normal differentiation 
capacity and a similar morphology compared with BM‑MSCs 
derived from healthy controls. Aliquots of 5‑10 ml adult donor 
bone marrow aspirates (five from patients with NMO and five 
from age‑ and sex‑matched healthy subjects) were provided by 
the Department of Hematology of Tianjin Medical University 
General Hospital. After isolation, BM‑MSCs at passage 3 
were harvested to analyze their immunophenotype using flow 
cytometric analysis. BM‑MSCs from patients with NMO and 
healthy controls were revealed to express CD105, CD73, CD90, 
CD29, CD44 and CD166, although they lacked expression 
of CD34 and CD45 (Table IV). All the BM‑MSCs formed a 
monolayer of bipolar spindle‑like cells, with a ‘whirlpool‑like’ 
array. However, certain BM‑MSCs from the patients with 
NMO were observed to be aberrant, with an irregular and 
ragged appearance following staining with β‑tubulin under a 
fluorescence confocal microscope. Compared with the elon-
gated morphology of the BM‑MSCs from the healthy controls, 
certain BM‑MSCs from patients with NMO also exhibited a 
‘cobblestone'‑like’ appearance (Fig. 1A).
The differentiation capabilities of BM‑MSCs were subse-
quently investigated following induction with the differently 
conditioned media. BM‑MSCs were able to differentiate into 
osteoblasts and adipocytes, as tested by positive staining of 
ALP and Alizarin Red S (for osteoblasts), and Oil Red O (for 
adipocytes). The results revealed that the BM‑MSCs from 
the healthy controls and the patients with NMO were easily 
induced to differentiate into osteoblasts and the adipocyte 
lineage (Fig. 1B). There appeared to be no obvious differences 
in the differentiation capability between BM‑MSCs from 
either the healthy controls or the patients with NMO. These 
data indicated that there was little discrepancy in morphology 
between BM‑MSCs from healthy control subjects and the 
patients with NMO, since all the BM‑MSCs had very similar 
differentiation capabilities.
NMO patient‑derived BM‑MSCs exhibit decreased prolif‑
erative capability in vitro. The proliferative capability of 
the BM‑MSCs was measured using a non‑radioactive MTT 
assay method. The extent of cell proliferation was measured 
following culture for 0, 1, 2, 3 and 4 days, in a regular MSC 
culture medium. As presented in Fig. 2A, the proliferation 
rate of BM‑MSCs from the patients with NMO was decreased 
compared with the healthy controls from day 3. However, 
following 4 days of culture, the proliferation of the BM‑MSCs 
from the patients with NMO was significantly decreased 
(P<0.05). In addition, along with the proliferation assay, the 
mRNA expression levels of an array of cell cycle‑ and prolif-
eration‑associated genes in the BM‑MSCs from the patients 
with NMO and healthy controls were detected by RT‑qPCR 
(Fig. 2B and C). These experiments revealed that the expres-
sion levels of AREG and CCNA2 were significantly decreased 
in BM‑MSCs from the patients with NMO compared with the 
healthy controls (P<0.05), whereas the expression of CDKN2A 
significantly increased in the patient group (P<0.05). Changes 
in the protein levels of the above genes revealed a similar 
tendency. Three experimental subjects were randomly selected 
from the NMO patient group and the healthy subject group, 
respectively, and these exhibited the same tendency (Fig. 3A 
and B). These data suggested that the proliferative capa-
bilities of BM‑MSCs from the patients with NMO were lower 
compared with those of BM‑MSCs from the healthy controls.
NMO patient‑derived BM‑MSCs exhibit increased senes‑
cence in vitro. The viability of BM‑MSCs was subsequently 
compared between the patients with NMO and the healthy 
controls, as indicated by the apoptotic rate of BM‑MSCs 
under normal culture conditions. As presented in Fig. 4, the 
apoptotic rate of BM‑MSCs from the patients with NMO 
was three times higher compared with the healthy controls. 
In addition, the expression levels of an array of cell apoptosis 
and cell death‑associated genes were compared between the 
two groups. Of the genes assessed, the expression of Fas was 
revealed to be significantly increased (P<0.05), whereas that 
of the pro‑survival gene Bcl‑xl was significantly decreased in 
BM‑MSCs from the patients with NMO at the mRNA and the 
protein levels (P<0.01; Fig. 4B‑D). These data suggested that 
senescence may be increased in the BM‑MSCs from patients 
with NMO compared with the healthy controls. Furthermore, 
the BM‑MSCs from patients with NMO were at a disadvantage 
in terms of their self‑renewal capability.
PDGF‑BB can stimulate cell proliferation and overcome 
the senescence disadvantage, of BM‑MSCs from patients 
with NMO. Several growth factors and cytokines have been 
considered to be critical factors regulating MSC proliferation, 
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Figure 1. Representative morphological and differentiation images of 
BM‑MSCs derived from patients with NMO and healthy controls. (A) The 
morphology of BM‑MSCs is presented following staining with β‑tubulin 
(red coloration). The nuclei of BM‑MSCs were stained with DAPI (indicated 
by the blue staining). The arrows indicate the ‘cobblestone‑like’ appearance 
of BM‑MSCs from the patients with NMO. (B) The osteogenic differentia-
tion capacity of BM‑MSCs was detected by positive staining of ALP (upper 
panel) and Alizarin Red (middle panel). The adipogenic differentiation 
capacity of BM‑MSCs was detected by positive staining of Oil Red O (lower 
panel). BM‑MSC, bone marrow‑derived mesenchymal stem cell; NMO, 
neuromyelitis optica; DAPI, 4',6‑diamidino‑2‑phenylindole; ALP, alkaline 
phosphatase.
Table IV. Continued
Genes Sequence (5'‑3')
DLG7 F: ACCTGGTCCAAGACAAAC
 R: CTGCTTTGCTGCTTGAGT
DLGAP5 F: CTACTCAAGCAGCAAAGC
 R: GGCAGGTCTTCCTTTACT
KITLG F: GTCATTGTTGGATAAGCG
 R: TCTGGGCTCTTGAATGAT
Table IV. Quantitative‑polymerase chain reaction primer 
sequences.
Genes Sequence (5'‑3')
AIF F: ATCTACAGGTGCTTCTGG
 R: GGCCTTTTTCTGTTTCTG
ATM F: GTGCCAGAATGATAAAGC
 R: GAAGCCAATACTGGACTG
BAX F: GACGGCAACTTCAACTGG
 R: GGAGGAAGTCCAATGTCC
Bcl‑xl F: GCTGGTGGTTGACTTTCT
 R: TCCATCTCCGATTCAGTC
Caspase 3 F: TCTGGAATATCCCTGGAC
 R: ATGTTTCCCTGAGGTTTG
Caspase 8 F: CCTGAGCCTGGACTACAT
 R: TCAGGAAGGACAGATTGC
CYCS F: GCCCCTGGATACTCTTAC
 R: GCCCTTTCTTCCTTCTTC
FADD F: GGTGTCGTCCAGCCTGTC
 R: TCCAGGTCGTTCTGCTCC
Fas F: GATGACCGTCGCTGGAAG
 R: CCATCGTGTGTGCCTGCT
FasL F: CTCCAGGCACAGTTCTTC
 R: GTGGTTCCCTCTCTTCTT
TNFSF10 F: ATGGCTATGATGGAGGTC
 R: AGAAACAAGCAATGCCAC
TRADD F: CAAAATGGGCACGAAGAG
 R: CGGTGGATCTTCAGCATC
CCNA2 F: ACAGTAAACAGCCTGCGTTC
 R: CAGGGCATCTTCACGCTCTA
CCNB1 F: GTGCCAGTGCCAGTGTCTGA
 R: CCATTGGGCTTGGAGAGGCA
CCNE2 F: TGTAACAATCATCTCCTGGC
 R: GGAGGTAAAATGGCACAAGG
CDC2 F: TAGAAAGTGAAGAGGAAGGG
 R: TACTGACCAGGAGGGATAGA
CDC20 F: CAAAGCCAAGGAAGCCGCAG
 R: TCACCGCCAGGTTTGCTAGG
CDK4 F: CGGTGCCTATGGGACAGTGT
 R: CAGTCGCCTCAGTAAAGCCA
CDK6 F: TGCTGAGGCACCTGGAGACC
 R: TCAGTGGGCACTCCAGGCTC
CDKN2A F: TTCCTGGACACGCTGGTGGT
 R: GGTTACTGCCTCTGGTGCCC
ORC5L F: ATACTGGATGCTTTGAGCCG
 R: TAGGCAGCATAGAAATCAGC
SMAD3 F: GCGGTCAAGAGCCTGGTCAA
 R: CACAGGCGGCAGTAGATGAC
YWHAZ F: ATGTTGTAGGAGCCCGTAGG
 R: TTTGCTCTCTGCTTGTGAAG
AREG F: GGTGCTGTCGCTCTTGAT
 R: GCATTTCACTCACAGGGG
CXCL1 F: CCCAAACCGAAGTCATAG
 R: CCTTCTGGTCAGTTGGAT
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migration and differentiation, among which PDGF is regarded 
as the most potent mitotic stimulatory factor (17,18). PDGFs 
are disulfide‑linked homodimers or heterodimers, consisting 
of several 12.0‑13.5 kDa polypeptide chains designated as the 
PDGF‑A, ‑B, ‑C and ‑D chains and the five naturally occur-
ring PDGFs are PDGF‑AA, PDGF‑BB, PDGF‑AB, PDGF‑CC 
and PDGF‑DD (18). Considering that PDGF‑BB is the major 
growth factor in bone matrix and its safety and effectiveness 
have been verified in a number of clinical trials (19,20), it 
seemed logical during these experiments to supplement the 
NMO BM‑MSC culture medium with PDGF‑BB in order 
to optimize the BM‑MSCs' biological properties. The MTT 
assay experiment revealed that 20 ng/ml PDGF‑BB was able 
to significantly promote the proliferation rate of BM‑MSCs 
from patients with NMO on days 3 and 4 (P<0.05; Fig. 5A). 
Furthermore, the cytometric images indicated that the apop-
totic rate of the NMO patient group was decreased from 
9.745±0.245% to 3.672±0.128% (P<0.01; Fig. 5B). Additionally, 
improvements at the molecular level were also confirmed 
by RT‑qPCR. As presented in Fig. 5C, the expression levels 
of AREG, CCNA2 and Bcl‑xl were significantly increased 
(P<0.01); conversely, the expression levels of CDKN2A and 
Fas were significantly decreased (all P<0.05). The protein 
expression levels following PDGF‑BB treatment in MSC cells 
from the identical patients were also examined. Three patients 
were selected and the protein expression levels of AREG, 
CCNA2 and Bcl‑xl were revealed to be significantly increased 
in the patients with NMO MSC with PDGF (P<0.05), whereas 
Figure 2. Expression patterns of proliferation and cell cycle‑associated genes of BM‑MSCs derived from patients with NMO and healthy controls. 
(A) Proliferation rate of the BM‑MSCs was detected using an MTT assay at the culture time points indicated. (B) The cell proliferation‑associated gene profile 
was determined using RT‑qPCR. (C) The cell cycle‑associated gene profile was determined using RT‑qPCR. *P<0.05 vs. the healthy control. BM‑MSC, bone 
marrow‑derived mesenchymal stem cell; NMO, neuromyelitis optica; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.
Figure 3. Different protein expression patterns of BM‑MSCs from patients 
with NMO and healthy controls. (A) Representative results of the protein 
expression patterns of AREG, CCNA2 and CDKN2A, as determined by 
western blot analysis, are presented. Samples #1, #2 and #3 were taken from 
the healthy volunteers, whereas samples #5, #6, #7 were from the NMO patient 
group. (B) The relative protein expression levels of AREG, CCNA2 and 
CDKN2A. For the western blot analysis, the protein bands were statistically 
analyzed with ImageJ software and β‑actin was used as an internal control. 
Results are presented as the mean ± standard deviation of three indepen-
dent experiments and each experiment was performed in triplicate. **P<0.01 
and ***P<0.001 vs. the healthy control. BM‑MSC, bone marrow‑derived 
mesenchymal stem cell; NMO, neuromyelitis optica; AREG, amphiregulin; 
CCNA2, cyclin A2; CDKN2, cyclin‑dependent kinase inhibitor 2A.
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the expression levels of Fas and CDKN2A were significantly 
decreased (P<0.01; Fig. 6A and B).
Discussion
NMO is a humoral immunity‑mediated inflammatory demyelin-
ating disease that preferentially targets the spinal cord and optic 
nerves (21). NMO is associated with a generally poor prognosis 
and the permanent myelin losses that precede and characterize 
the progressive stage of NMO remain untreatable (22). Stem cell 
transplantation has been considered to be a potential treatment 
method for neurological disorders due to the multifaceted roles 
of stem cells. Greco et al (23) applied hematopoietic stem cells 
to treat NMO and discovered that the treatment was able to 
reduce neuroinflammation and halt the progression of disability. 
By contrast, Matiello et al (24) demonstrated that autologous 
hematopoietic stem cell transplantation was unable to prevent 
the relapse of NMO (24). These results provide the foresight that 
caution is necessary in terms of selecting an appropriate type of 
stem cells to treat NMO.
MSCs have been extensively studied as cellular thera-
pies due to their various modes of action. MSCs exhibit 
numerous characteristics, including immune modulatory, 
neurotrophic (25) and repair‑promoting properties, which 
make them attractive candidates for treating various degenera-
tive neurological diseases, including stroke (26,27), multiple 
sclerosis (13,28) and Parkinson's disease (29,30). In 2012, 
Lu et al (31) reported that four out of five patients with NMO 
demonstrated therapeutic improvements following receiving 
human umbilical cord MSC therapy (31). However, the use 
of these allogeneic cells is associated with ethical concerns 
and the possibility of immunological rejection. Although the 
authors' recent clinical pilot observation revealed that the 
infusion of autologous MSCs provided beneficial effects in 
terms of lowering the relapse rate and disability in patients 
with NMO (15), further studies are required in order to focus 
on the cytological features of patient‑derived BM‑MSCs that 
may influence the therapeutic effects on patients with NMO. 
Therefore, the present study aimed to demonstrate whether the 
biological properties of BM‑MSCs from patients with NMO 
are different from those of BM‑MSCs taken from healthy 
control subjects. The results obtained revealed that there was 
no difference in the immune phenotype markers of BM‑MSCs, 
comparing between the patients with NMO and healthy 
Figure 4. The apoptotic rate and apoptosis‑associated gene expression patterns of BM‑MSCs from patients with NMO and healthy controls. (A) Representative 
dot plots of the apoptotic rate of BM‑MSCs are presented. (B) The global apoptosis‑associated gene expression profile of BM‑MSCs was determined using 
RT‑qPCR. (C) The protein expression levels of Bcl‑xl and Fas were determined by western blotting and representative results are presented. Samples #1, #2 
and #3 were taken from the healthy volunteers, whereas samples #5, #6, #7 were from the NMO patient group. (D) Relative protein expression levels of Bcl‑xl 
and Fas. For the western blot analysis, the protein bands were statistically analyzed with ImageJ software and β‑actin was used as an internal control. Results 
are presented as the mean ± standard deviation of three independent experiments and each experiment was performed in triplicate. *P<0.05 and **P<0.01 
vs. the healthy controls. BM‑MSC, bone marrow‑derived mesenchymal stem cell; NMO, neuromyelitis optica; RT‑qPCR, reverse transcription‑quantitative 
polymerase chain reaction; FITC, fluorescein isothiocyanate; PI, propidium iodide.
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controls. The appearances of certain of the BM‑MSCs from 
the patients with NMO were revealed to be slightly aberrant, 
even though they exhibited a normal differentiation capability; 
however, the BM‑MSCs from patients did reveal decreased 
proliferative capacity and increased senescence.
In addition to the observed biological phenomena, it 
was determined that an array of cell cycle, proliferation and 
apoptosis‑associated gene expression profiles varied between 
the BM‑MSCs derived from the patients with NMO and the 
healthy controls. Decreased expression levels of AREG have 
been demonstrated to induce abnormalities of homeostasis 
and to decrease cell proliferation (32). In addition, CDKN2A is 
a gene that can induce arrested cell growth. The activation of 
CDKN2A may inhibit the cell cycle transition from G1 to the S 
phase by inhibiting cyclin‑dependent kinases (CDKs). CCNA2 
belongs to the cyclin family that regulates the S phase of cell 
cycle progression by interacting with CDKs and decreased 
CCNA2 may arrest the cell cycle at S phase. Therefore, aberrant 
expression of CKDN2A and CCNA2 may lead to maladjusted 
cell growth. In the present study, the expression levels of Fas 
in the patients with NMO were increased compared with those 
of healthy controls. The Fas receptor is a death receptor on 
the surface of cells that initiates programmed cell death when 
bound to its ligand, Fas‑L and an increasing number of reports 
have demonstrated that Fas overexpression is associated with 
apoptosis and cell senescence (33‑35). Bcl‑xL is a canonical 
anti‑apoptotic protein in the Bcl‑2 family. Bcl‑xL inhibits Bak 
or Bax activation, which is an essential event for apoptosis and 
senescence execution (36,37).
PDGF signaling pathways have long been demonstrated 
to be involved in pre‑ and post‑natal vasculogenesis and/or 
angiogenesis. PDGFs are potent mitogens for MSCs and are 
involved in their growth and differentiation. PDGF isoforms 
exert their biological effects via the activation of two tyrosine 
kinase receptors, PDGF receptor‑α (PDGFR)‑α and PDGFR‑β, 
which are abundantly expressed on MSCs (17). Studies have 
been published on a large number of successful applications 
of PDGF‑BB‑based therapies for various types of maladies, 
including tendon and bone fracture repairs, and demyelin-
ating disease (20,38). For example, Chen et al (19) performed 
PDGF‑BB‑based stem cell gene therapy to improve bone 
strength in hematopoietic stem cell transplantation subjects 
and in their in vivo model the proliferation of BM‑MSCs 
increased significantly compared with the control group (19).
In order to find the potential mechanism of different cyto-
logical features of BM MSCs from patients with NMO and 
healthy subjects, 28 genes involved in the cell cycle, prolif-
eration and cell apoptosis were screened with the RT‑qPCR 
Figure 5. PDGF‑BB can stimulate proliferation and overcome the senescence disadvantage, of BM‑MSCs from patients with NMO. (A) The proliferation curve of 
BM‑MSCs from patients with NMO treated with PDGF‑BB (20 ng/ml) is presented. (B) Representative dot plots demonstrating the apoptotic rate of BM‑MSCs 
from patients with NMO treated with PDGF‑BB (20 ng/ml). (C) mRNA levels of AREG, CCNA2, CDKN2A and Fas genes in BM‑MSCs from patients with 
NMO treated with PDGF‑BB (20 ng/ml), as determined using RT‑qPCR are presented. *P<0.05 and **P<0.01 vs. the controls. BM‑MSC, bone marrow‑derived 
mesenchymal stem cell; NMO, neuromyelitis optica; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction; AREG, amphiregulin; CCNA2, 
cyclin A2; CDKN2, cyclin‑dependent kinase inhibitor 2A; PGDF‑BB, platelet‑derived growth factor‑BB; FITC, fluorescein isothiocyanate; PI, propidium iodide.
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method and found the genes, which were differentially 
expressed in two kinds of BM‑MSCs, could be divided into 
two groups: Cell cycle associated genes like AREG, CCNA2 
and CDKN2A, and cell program death associated genes like 
Bcl‑xl and Fas. The results of the present study demonstrated 
the expression of CCNA2 and Fas increased, and the expres-
sion of CDKN2A and Bcl‑xl was decreased in BM‑MSCs from 
patients with NMO. A wide range of evidence indicates that 
CCNA2 is implicated in the initiation and progression of DNA 
synthesis and involved in the G2/M transition, and CDKN2A 
could inhibit the cell cycle through blocking transition from 
G1 to S phase. In addition, Bcl‑xl acts as an anti‑apoptotic 
protein by preventing the release of cytochrome c. Fas, a death 
receptor on the surface of cells, can lead to programmed cell 
death (32‑37). In addition, the results of the present study are 
consistent with the above reports and the cytological features 
observed. Furthermore, the results suggest that these proteins 
may act as promising targets for the defected cytological 
features of BM‑MSCs from patients with NMO. Moreover, 
the synergetic effects from two different proteins on the same 
cell signaling pathway may serve critical roles in that progress. 
However, whether there is a regulatory network or interaction 
between these proteins needs to be further investigated.
In conclusion, it has been demonstrated in the present 
study that, although the BM‑MSCs from patients with NMO 
exhibited a similar cell morphology and differentiation ability 
when compared with the healthy controls, the cells grew 
more slowly and tended to be a little more inclined towards 
senescence. These aberrant changes in cytological features 
of patient‑derived BM‑MSCs could influence the therapeutic 
effects of autologous BM‑MSC infusion treatment in NMO. 
Promising approaches to overcome the above‑mentioned 
defects were to routinely add PDGF in vitro during the expan-
sion phase of the BM‑MSCs, or to combine PDGF cytokine 
therapy with BM‑MSC infusion in refractory patients with 
NMO. Although the present study has provided a theoretical 
basis for treatment of NMO, further studies are required in 
view of the limited number of patients with NMO. In addi-
tion, the immune modulatory and neurotrophic effects of these 
cells that were not included in this study also require further 
investigation.
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